专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11732266B2 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof 有权
公开(公告)号：US11732266B2
公开(公告)日：2023-08-22
申请号：US17080771
申请日：2020-10-26
申请人： AMGEN INC.
发明人： Michael Ollmann , Yang Li , Jun Zhang , Oliver Homann , Leslie P. Miranda , Justin K. Murray , Bin Wu , Oh Kyu Yoon , John Gordon Allen , Chawita Netirojjanakul , Yuan Cheng
IPC分类号： C12N15/113 , A61P9/10 , A61P3/06 , C07K16/28
CPC分类号： C12N15/1138 , A61P3/06 , A61P9/10 , C07K16/2851 , C07K2317/526 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/321 , C12N2310/332 , C12N2310/351 , C12N2310/3513 , C12N2310/321 , C12N2310/3521 , C12N2310/322 , C12N2310/3533 , C12N2310/322 , C12N2310/3531
摘要： The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

2. 发明授权

US11248052B2 Antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor 有权
公开(公告)号：US11248052B2
公开(公告)日：2022-02-15
申请号：US16282834
申请日：2019-02-22
申请人： Amgen, Inc.
发明人： Yang Li , Jennitte LeAnn Stevens , Chadwick Terence King , Ian Nevin Foltz , Gunasekaran Kannan , Junming Yie , Shaw-Fen Sylvia Hu
IPC分类号： C07K16/28 , C07K14/71 , C07K16/40 , A61K39/00
摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing β-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.

3. 发明申请

US20210163601A1 ASGR INHIBITORS 有权
公开(公告)号：US20210163601A1
公开(公告)日：2021-06-03
申请号：US16987237
申请日：2020-08-06
申请人： Amgen Inc.
发明人： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC分类号： C07K16/28 , A61P9/10 , A61P9/04 , C12N15/113 , C07H21/02 , A61P3/06 , A61K39/395 , A61K45/06
摘要： Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

4. 发明申请

US20190248902A1 ASGR INHIBITORS 审中-公开
公开(公告)号：US20190248902A1
公开(公告)日：2019-08-15
申请号：US16230356
申请日：2018-12-21
申请人： Amgen Inc.
发明人： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC分类号： C07K16/28 , C07H21/02 , A61K39/395 , A61P9/10 , A61P9/04 , A61K45/06 , C12N15/113
CPC分类号： C07K16/2851 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C07K16/28 , C07K2317/30 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N15/1138
摘要： Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

5. 发明授权

US09850297B2 Secreted frizzle-related protein 5 (SFRP5) binding proteins 有权
公开(公告)号：US09850297B2
公开(公告)日：2017-12-26
申请号：US14776012
申请日：2014-03-14
申请人： AMGEN INC.
发明人： Jiangwen Majeti , YuMei Xiong , Wen-Chen Yeh , Alykhan S. Motani , Yang Li
IPC分类号： C07K16/18 , C12N5/10 , C12N15/10 , C12N15/11 , A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/14 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the SFRP5 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.

6. 发明授权

US09493577B2 Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof 有权
标题翻译：结合β-klotho，FGF受体及其复合物的人抗原结合蛋白
公开(公告)号：US09493577B2
公开(公告)日：2016-11-15
申请号：US15012939
申请日：2016-02-02
申请人： Amgen Inc.
发明人： Shaw-Fen Sylvia Hu , Ian Nevin Foltz , Chadwick Terence King , Yang Li , Taruna Arora
IPC分类号： A61K39/395 , C07K16/40 , C07K14/71 , C07K16/18 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K14/71 , C07K16/18 , C07K16/28 , C07K16/40 , C07K2317/21 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/75 , C07K2317/92 , C07K2319/30
摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
摘要翻译：本发明提供与抗原结合蛋白有关或衍生自抗原结合蛋白的组合物和方法激活FGF21介导的信号传导。在实施方案中，抗原结合蛋白特异性结合（i）β-Klotho; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。在一些实施方案中，抗原结合蛋白诱导FGF21样信号传导。在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，所述抗体的结合片段和衍生物，以及特异性结合（i）β-Klotho的多肽; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。其它实施方案提供了编码这种抗原结合蛋白的核酸及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物以及多肽，以及使用这些抗原结合蛋白的方法，其片段及其衍生物和多肽，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症的受试者的方法。

7. 发明授权

US09474792B2 Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides 有权
标题翻译：使用PLA2G12A多肽和PLA2G12A突变体多肽治疗代谢紊乱的方法
公开(公告)号：US09474792B2
公开(公告)日：2016-10-25
申请号：US14772910
申请日：2014-03-13
申请人： AMGEN INC.
发明人： Daniel C. H. Lin , Jinghong Wang , Yang Li
IPC分类号： A61K38/46 , A61B5/145 , C12N9/20
CPC分类号： A61K38/465 , A61B5/14532 , C12N9/20 , C12Y301/01004
摘要： Methods of treating or ameliorating metabolic diseases using a PLA2G12A polypeptide or PLA2G12A mutant polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes mellitus, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.
摘要翻译：提供了使用PLA2G12A多肽或PLA2G12A突变体多肽治疗或改善代谢疾病的方法。在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。

8. 发明授权

US10870856B2 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof 有权
公开(公告)号：US10870856B2
公开(公告)日：2020-12-22
申请号：US16328221
申请日：2017-08-25
申请人： AMGEN INC.
发明人： Michael Ollmann , Yang Li , Jun Zhang , Oliver Homann , Leslie P. Miranda , Justin K. Murray , Bin Wu , Oh Kyu Yoon , John Gordon Allen , Chawita Netirojjanakul
IPC分类号： C12N15/113 , A61P9/10 , A61P3/06 , C07K16/28
CPC分类号： C12N15/1138 , A61P3/06 , A61P9/10 , C07K16/2851 , C07K2317/526 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/321 , C12N2310/332 , C12N2310/351 , C12N2310/3513 , C12N2310/321 , C12N2310/3521 , C12N2310/322 , C12N2310/3533 , C12N2310/322 , C12N2310/3531
摘要： The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

9. 发明申请

US20130143796A1 CHIMERIC POLYPEPTIDES AND USES THEREOF 审中-公开
标题翻译： CHIMERIC POLYPEPTIDES及其用途
公开(公告)号：US20130143796A1
公开(公告)日：2013-06-06
申请号：US13680986
申请日：2012-11-19
申请人： AMGEN INC.
发明人： Yang Li , Xinle Wu , Zhulun Wang
IPC分类号： C07K14/50
CPC分类号： C07K14/50 , C07K16/22 , C07K2319/00
摘要： The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions.
摘要翻译：本公开内容提供了编码嵌合多肽的核酸分子，嵌合多肽，包含嵌合多肽的药物组合物，以及使用这种核酸，多肽或药物组合物治疗代谢性疾病如糖尿病和肥胖症的方法。

10. 发明授权

US10570205B2 Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof 有权
公开(公告)号：US10570205B2
公开(公告)日：2020-02-25
申请号：US15280662
申请日：2016-09-29
申请人： AMGEN INC.
发明人： Shaw-Fen Sylvia Hu , Ian Nevin Foltz , Chadwick Terence King , Yang Li , Taruna Arora
IPC分类号： A61K39/00 , C07K16/28 , C07K16/40 , C07K14/71 , C07K16/18
摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式